Biogen Presents Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab at 2016 Clinical Trials on Alzheimer’s Disease Meeting

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. SPY
4. ABBV
5. META
6. ACN
7. BLZE
8. IBM
9. NKE
10. MU

Go back to Biogen Presents Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab at 2016 Clinical Trials on Alzheimer’s Disease Meeting

Mizuho Discusses Biogen (BIIB) Seizure Patient

December 9, 2016 2:15 PM EST

Mizuho analyst Salim Syed discussed Biogen (NASDAQ: BIIB) Aducanumab's LTE seizure patient, which has the stock well off highs (+0.4%).

"On the seizure patient, we spoke to the company (they weren't willing to say much beyond the slide) ... this is a new... More

Biogen (BIIB) PT Raised to $309 at Baird on Additional Sola Details

December 9, 2016 6:34 AM EST

Baird analyst Brian Skorney raised his price target on Biogen (NASDAQ: BIIB) to $309.00 (from $284.00) following additional sola details. The firm stopped short of upgrading the stock, however, and maintained a Neutral rating.

Skorney commented, "Lilly reported additional quantitative results from the Phase 3... More